Mutated EGFR-IN-1

Overview

Mutated EGFR-IN-1 (Osimertinib analog) (Intermediate 168) is a structural analog of Osimertinib ( HY-15772 ) and can be used as a pharmaceutical intermediate for EGFR inhibitors.

Application

Products | Products > Disease Areas > Lipid Metabolism | Products > Disease Areas > Lung Cancer | Products > Disease Areas > Colorectal Cancer | Products > Disease Areas > Digestive System Cancer | Products > Disease Areas > Prostate Cancer | Products > Disease Areas > Urogenital Cancer | Products > Disease Areas > Liver Cancer | Products > Disease Areas > Pancreatic Cancer | Products > Disease Areas > Ovarian Cancer | Products > Disease Areas > Hepatitis C Virus Infection | Products > Disease Areas > Obesity | Products > Disease Areas > Cancer | Products > Disease Areas > Infection | Products > Disease Areas > Metabolic or Endocrine Disease | Products > Disease Areas > Digestive System Disease | Products > Disease Areas > Urogenital Disease | Products > Disease Areas > Hepatitis Virus Infection | Products > Signaling Pathways > Others | Products > Research Areas > Metabolic Disease | Products > Research Areas > Infection | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Drug Resistance | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > Drug Derivative

Product Information

• Catalog No.: HY-78869
• CAS No.: 1421372-66-8
• Molecular Formula: C25H31N7O
• Molecular Weight: 445.56
• Purity: 99.90%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
• Availability: In-stock

Source

Original product source